Skip to content
NASDAQ · SERVICES-MEDICAL LABORATORIES · MID CAP

Fortrea Holdings Inc. FTRE

5 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.7B
▲ 1.0% YoY
$-986.2M
$88.3M
▼ 62.8% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Fortrea provides phase I through IV clinical trial management, clinical pharmacology, and consulting services for its customers. Its team of approximately 14,300 employees conducts operations in approximately 100 countries. As of the fiscal year ended 2025, one customer accounted for approximately 18.1% of its revenue. It manages its business in one reporting segment, Clinical Services. Fortrea's clinical research units are located in Leeds, U.K., Dallas, Texas, Daytona, Florida, and Madison, Wisconsin. It provides consulting services spanning product development and regulatory strategy to market access and health economics and outcomes research. Fortrea Holdings Inc. was formed through a spin-off of the CRO business from Labcorp Holdings Inc.

Written from the business description in Fortrea Holdings Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 2.7B
Revenue, FY2025 · full 5-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.7 · Net income -1.0
1.5B3.0B-0.4B-0.8B
202120242025
Compound annual growth
−1.4%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−36 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -32.0% · Net -36.2%
2%4%6%-10%-20%-30%
202120232025
ROE
FY2025 · ROE -102.4%
-50%-100%
202120232025
Three returns, three denominators.

Each USD of equity lost 102 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 88.3
100M200M
202120232025

Total assetsUSD 2.7B
EquityUSD 563.5M
CashUSD 174.6M
Gross debtUSD 1.1B
Net debtUSD 878.2M
Current ratio0.98×

Net debt stands at 156% of equity.

The 5-year record

5 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
FTRE, 5-year financial record
Metric 20252024202320222021
Revenue $B2.72.72.82.83.1
Operating income $B−0.9−0.20.00.20.1
EBITDA $B−0.8−0.10.10.30.3
Income tax $B0.0−0.00.00.00.0
Net income $B−1.0−0.3−0.00.20.1
Free cash flow $B0.10.20.10.00.1
EPS, diluted $−10.81−3.67−0.292.091.10
Dividend / sh $◌◌◌◌◌
Payout % — not applicable: no dividend—————
ROE %−102.4−21.4−1.05.63.0
Shares out B0.090.090.090.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 15 reconciliationsAUDITED

Reconciled in 5 of the 5 fiscal years we could check. 30 checks were skipped: the balance sheet is not tagged before 2022. 14 checks were skipped: EPS is not tagged before 2021. 14 checks were skipped: revenue is not tagged before 2021.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityServices-Medical Laboratories
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2021

Share this section

Download image